Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
Summit Therapeutics sold its Phase III asset ridinilazole to Biossil, Inc. for $500,000 upfront and potential milestones of up to $104.5 million. The transaction allows Summit to prioritize its core oncology strategy and the development of ivonescimab, exiting a program that previously failed to meet its primary endpoint.
Key figures
- Drug Name
- Ridinilazole
- Phase Of Trial
- Phase III
- Upfront payment usd
- 500000
- Potential milestones usd
- 104500000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.